Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:37:35 2026-04-17 am EDT			Pre-market 01:48:15 am
41.10 ^EUR	+1.01%		40.44	-1.61%

Apr. 17	US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims	RE
Apr. 17	U.S. judge rejects Bayer's request for injunction to block Johnson & Johnson's alleged false statements about prostate cancer drug	RE

Health Care Up, But not by Much, on Cyclical Bias - Health Care Roundup

Published on 03/04/2026 at 05:37 pm EST

Dow Jones

BAYER AG

+1.01%

MODERNA, INC.

-1.76%

ARBUTUS BIOPHARMA CORPORATION

+0.85%

Health-care companies rose, but not by as much as the broad market, as traders rotated into cyclical sectors.

Bayer posted a steeper net loss for the fourth quarter, as it booked litigation charges as part of its yearslong court battles over its Roundup weedkiller. Bayer said growth of its Kerendia drug for kidney disease would partially offset the loss of patent protection of blood thinner Xarelto and eye medicine Eylea.

Vaccine maker Moderna agreed to pay $950 million to settle patent litigation by Arbutus Biopharma and Genevant Sciences GmbH.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

03-04-26 1736ET

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Approximate price	Change	5d. change	Capi.
BAYER AG	41.10EUR	+1.01%	+2.44%	47.67B
MODERNA, INC.	53.72USD	-1.76%	+5.42%	21.3B
ARBUTUS BIOPHARMA CORPORATION	4.720USD	+0.85%	+13.73%	923M

Latest news about Bayer AG

Apr. 17	US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims	RE
Apr. 17	U.S. judge rejects Bayer's request for injunction to block Johnson & Johnson's alleged false statements about prostate cancer drug	RE
Apr. 17	Tyra Biosciences Announces Board Changes	CI
Apr. 16	German DAX Extends Gains Amid Growing Hopes to End of Iran War	MT
Apr. 16	BAYER AG : Deutsche Bank reiterates its Neutral rating	ZD
Apr. 16	Bayer's Asundexian stroke trial shows fewer ischemic events, no bleeding risk - NEJM	RE
Apr. 14	Amazon launches AI platform to accelerate drug discovery
Apr. 14	Amazon launches AI research tool to speed early-stage drug discovery	RE
Apr. 13	ImmuCell Corporation Announces Board Changes	CI
Apr. 13	Lineage Cell Therapeutics, Inc. Announces Formation of Scientific Advisory Board and Executive Appointment	CI
Apr. 13	BAYER AG : Gets a Buy rating from UBS	ZD
Apr. 10	DZ Bank AG Research Upgrades Bayer to Hold, Lifts PT	MT
Apr. 10	Dax searches for direction as US inflation takes center stage	RE
Apr. 09	BAYER AG : DZ Bank Upgrades to Neutral	ZD
Apr. 09	DZ Bank Upgrades Bayer to 'Hold' - Fair Value Raised to 44 Euros	DP

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.5%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (39.1%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.7%), Switzerland (1%), Europe-Middle East-Africa (22.9%), United States (33.1%), North America (3.6%), China (7.6%), Asia-Pacific (8.9%), Brazil (9.6%), and Latin America (7.6%).

Employees

87,280

Sector

Pharmaceuticals

Calendar

Apr. 27 - Ex-dividend date - 0.11 EUR

More about the company